OrbiMed’s DaVita DVA Stock Holding History

OrbiMed’s Portfolio DVA Stock Details DVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-534,000	Closed	-$27.5M	–	132
2018 Q4	$27.5M	Sell	534,000 -911,700	-63%	-$58.4M	0.51%	58
2018 Q3	$104M	Sell	1,445,700 -243,700	-14%	-$17.2M	1.25%	23
2018 Q2	$117M	Buy	1,689,400 +129,800	+8%	+$8.67M	1.4%	22
2018 Q1	$103M	Buy	1,559,600 +1,082,200	+227%	+$79.5M	1.28%	25
2017 Q4	$34.5M	Buy	+477,400	New	+$29.4M	0.44%	64
2015 Q2	–	Sell	-76,000	Closed	-$6.18M	–	142
2015 Q1	$6.18M	Hold	76,000	–	–	0.05%	116
2014 Q4	$5.76M	Buy	76,000 +11,000	+17%	+$828K	0.06%	109
2014 Q3	$4.75M	Hold	65,000	–	–	0.05%	114
2014 Q2	$4.7M	Sell	65,000 -78,000	-55%	-$5.42M	0.06%	112
2014 Q1	$9.85M	Hold	143,000	–	–	0.12%	92
2013 Q4	$9.06M	Buy	143,000 +13,000	+10%	+$763K	0.13%	83
2013 Q3	$7.4M	Hold	130,000	–	–	0.13%	91
2013 Q2	$7.85M	Buy	+130,000	New	+$8.12M	0.17%	85

Other funds holding DVA

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GCM

Gates Capital Management New York $3.66B AUM 12.63% 1-Year Est. Return

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed's DVA Position: Q1 2019 in Review

OrbiMed sold out of DaVita (DVA) in Q1 2019, closing a stake of 534,000 shares — an estimated $27.5M sold.

OrbiMed first reported a position in DVA in Q2 2013 and held it in 13 quarters. The position peaked at $117M in Q2 2018. 440 funds tracked by Wall St. Rank hold DVA as of Q1 2019.

OrbiMed reported no remaining DaVita position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 534,000 DaVita shares in Q1 2019, an estimated $27.5M.
OrbiMed first reported a position in DaVita in Q2 2013 and held it in 13 quarters.
OrbiMed's DaVita position peaked at $117M in Q2 2018.
440 funds tracked by Wall St. Rank held DaVita as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.